Skip to main content

Table 2 Cycle characteristics and outcomes

From: Degenerated oocyte in the cohort adversely affects IVF outcome

Characteristic Non DEG group (n = 318) DEG group (n = 81) P-value
Estradiol on hCG trigger day (pgr/dl) 1638 ± 798 1990 ± 1304 0.002
Progesterone level at hCG trigger day 0.67 ± 0.45 0.74 ± 0.47 NS
Endometrium (mm) 9.7 ± 2.3 9.6 ± 2.2 NS
Duration of treatment (days) 9.9 ± 2.6 10.5 ± 2.6 NS
Protocol Number/total cycles (%)
 Long Protocol 51 (16.2) 21 (27.6) 0.03
 Flare/Short agonist 26 (8.3) 11 (14.5) NS
 Antagonist 233 (74) 44 (57.9) 0.007
 Modified natural cycle 4 (1.3%) 0 NS
Treatment outcome
 Number of Oocyte collected 10.1 ± 6.1 12.9 ± 7.2 P < 0.001
 M2 7.3 ± 4.4 8.4 ± 4.9 P = 0.063
 2PN 5.8 ± 3.8 6.2 ± 3.9 NS
 KID 3.4 ± 1.6 3.2 ± 1.6 P = 0.002
 ESHRE 1.5 ± 1.1 1.4 ± 1.0 P = 0.046
 KID =4 + 5 (Top quality embryo) 1174 (58.8%) 314 (53.0%) P = 0.012
 ESHRE 2 + 3 (Top quality embryo) 1041 (52.2%) 282 (47.6%) P = 0.049
 TOP quality embryo (combined score of- 5,3/5,2/4,3/4,2) 965/1995 (48.4%) 257/593 (43.3%) P = 0.031
 Chemical pregnancy/cycle 105/318 (38.5%) 32 (39.5%) NS
 Clinical pregnancy/cycle 105/318 (38.5%) 29 (35.8%) NS
  1. DEG Degenerated oocyte, hCG Human chorionic gonadotropin